NRX Pharmaceuticals, headquartered in Wilmington, Delaware, is a clinical-stage biopharmaceutical company specializing in treatments for central nervous system disorders, including its lead compounds NRX-100 and NRX-101. The company went public on November 20, 2017, and is developing therapies targeting bipolar depression, chronic pain, and PTSD.